Press Release - For Immediate Release

CLEARBRIDGE BIOMEDICS INKS PRE-IPO FUNDING, MOVES TOWARDS DEVELOPING END-TO-END DIAGNOSTIC TESTS

- **The pre-IPO funding round attracted investments from oncology medical professionals as well as investors focused in healthcare and biotechnology**
- **Funds will be used for business expansion, technology development, talent recruitment and IPO-related expenses to develop end-to-end cancer diagnostic tests**
- **Barring unforeseen circumstances, the Company's IPO is expected to be launched in the last quarter of 2018**

Singapore, 28 June 2018 – Singapore-based medical technology company, **Clearbridge BioMedics Pte Ltd ("Clearbridge BioMedics" or "the Company"),** a cancer diagnostics solutions company, is pleased to announce that it has attracted S$6.6 million in pre-IPO funding.

Pioneering patented, award-winning microfluidics technology, Clearbridge BioMedics is leading the advancement of non-invasive liquid biopsy for real time analysis of cancer cells, providing vital and accurate information for higher standard of healthcare treatment in an era of precision medicine. In addition, unlike conventional diagnostic treatments, Clearbridge BioMedics's cancer diagnostics solutions can potentially lower medical costs and at the same time, reduce inconvenience for patients.

This pre-IPO funding follows major milestones the Company has achieved, including:

- Spin-off from National University of Singapore and Singapore-MIT Alliance for Research and Technology (SMART Centre), backed by the Singapore government's National Research Foundation
- Pioneered a novel method for isolating cancer cells from a simple standard blood draw through technology that is non-invasive, while providing real-time information on cancer
- Successful commercialization of its ClearCell® FX1 System in 2015 with global deployments in leading cancer institutes and hospitals
- Attained various industry certifications and registrations such as Europe's CE IVD certification, United States' US-FDA Registration, and China's CFDA Registration via our Chinese partner
- Expansion of ClearCell®FX1 System to EMEA and APAC regions through partnerships with 12 new distributors

"Clearbridge BioMedics is leading a transformation around cancer treatments focused on non-invasive liquid biopsy. This enables real-time analysis of wholly intact cancer cells from a standard blood draw, enabling medical professionals to better understand and manage their patients, and potentially improving cancer disease management and outcomes.

This pre-IPO funding will enable us to accelerate our growth and create a differentiated, cost-effective and sustainable model of diagnostic solutions in Asia. Barring unforeseen circumstances, we look forward to launching our IPO in the last quarter of 2018." **said Mr Johnson Chen, Chairman and Founder of Clearbridge BioMedics.**

With a veteran leadership team who bring together strong business, clinical, and engineering capabilities to execute on a unique core technology and scalable business model, Clearbridge BioMedics is a spin-off from the National University of Singapore / SMART MIT and it is the first incubatee of Clearbridge Accelerator (now known as Clearbridge Health Limited [SGX:1H3], a company listed on the Singapore Exchange), a high-technology incubator backed by the Singapore Government's National Research Foundation and Enterprise Singapore.

– END –

About Clearbridge BioMedics

Clearbridge BioMedics Pte Ltd. is a clinical stage cancer diagnostics company that develops and manufactures liquid biopsy systems. Clearbridge BioMedics is based in Singapore and has commercially launched the ClearCell® FX platform to laboratories around the globe. Clearbridge BioMedics has won numerous awards and garnered global recognition for its novel Circulating Tumor Cell (CTC) detection platform technology, the ClearCell® FX System. The ClearCell® FX System and its biochip are utilizing state-of-the-art, non-invasive liquid biopsy to analyze blood samples for circulating tumor cells (CTCs). The device allows for real time analysis of disease before, during, and after treatment, which has become increasingly critical in the new era of targeted cancer therapies.

Clearbridge BioMedics has received ISO 13485 certification in 2011 and the ClearCell® FX System attained CE IVD in 2015 and US FDA Class 1 registration in 2017. In China, the same system is available as China FDA approved Class 1 system as the EasyCell system, through a partnership with MGI (an associate of Beijing Genomics Institute (BGI)).

For more information, visit www.ClearbridgeBioMedics.com.
Product Video https://youtu.be/6go64NOgaRk

Media & Investor Contact

Mr. Alex TAN
Mobile: +65 9451 5252
Email: alex.tan@8prasia.com